Innate immune recognition and suppression of tumors
- PMID: 16860661
- DOI: 10.1016/S0065-230X(06)95008-8
Innate immune recognition and suppression of tumors
Abstract
In this chapter, we first summarized the strong evidence that now supports the existence of an effective cancer immune surveillance process that prevents cancer development in both mice and humans. We then focused the remainder of the chapter on methods of tumor recognition that contribute to natural host immune suppression of tumors. In particular, NKG2D is a type II transmembrane-anchored glycoprotein expressed as a disulfide-linked homodimer on the surface of all mouse and human natural killer cells (NK cells). Stimulation of NK cell through NKG2D triggers cell-mediated cytotoxicity and in some cases induces production of cytokines. NKG2D binds to family of ligands with structural homology to major histocompatibility complex (MHC) class I, however, NKG2D ligands often display upregulated surface expression on stressed cells and are frequently overexpressed by tumors unlike conventional MHC class I molecules. Evidence clearly implicate that NKG2D recognition plays an important role in tumor immune surveillance.
Similar articles
-
NKG2D and cytotoxic effector function in tumor immune surveillance.Semin Immunol. 2006 Jun;18(3):176-85. doi: 10.1016/j.smim.2006.03.005. Epub 2006 May 3. Semin Immunol. 2006. PMID: 16675266 Review.
-
Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.Cancer Res. 2005 Jul 15;65(14):6321-9. doi: 10.1158/0008-5472.CAN-04-4252. Cancer Res. 2005. PMID: 16024634
-
A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.Eur J Immunol. 2003 Feb;33(2):381-91. doi: 10.1002/immu.200310012. Eur J Immunol. 2003. PMID: 12645935
-
Imbalance of NKG2D and its inhibitory counterparts: how does tumor escape from innate immunity?Int Immunopharmacol. 2005 Jul;5(7-8):1099-111. doi: 10.1016/j.intimp.2005.03.003. Epub 2005 Apr 1. Int Immunopharmacol. 2005. PMID: 15914316 Review.
-
NKG2D ligands: key targets of the immune response.Trends Immunol. 2008 Aug;29(8):397-403. doi: 10.1016/j.it.2008.04.007. Epub 2008 Jul 3. Trends Immunol. 2008. PMID: 18602338 Review.
Cited by
-
Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.Front Immunol. 2021 Mar 9;12:636568. doi: 10.3389/fimmu.2021.636568. eCollection 2021. Front Immunol. 2021. PMID: 33767702 Free PMC article. Review.
-
In Vivo Efficacy of Umbilical Cord Blood Stem Cell-Derived NK Cells in the Treatment of Metastatic Colorectal Cancer.Front Immunol. 2017 Feb 6;8:87. doi: 10.3389/fimmu.2017.00087. eCollection 2017. Front Immunol. 2017. PMID: 28220124 Free PMC article.
-
Anti-cancer activity and mechanistic features of a NK cell activating molecule.Cancer Immunol Immunother. 2009 Oct;58(10):1691-700. doi: 10.1007/s00262-009-0680-0. Epub 2009 Mar 4. Cancer Immunol Immunother. 2009. PMID: 19259669 Free PMC article.
-
Natural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspective.Front Immunol. 2014 Sep 15;5:439. doi: 10.3389/fimmu.2014.00439. eCollection 2014. Front Immunol. 2014. PMID: 25309538 Free PMC article. Review.
-
Extraction, Characterization, Antitumor and Immunological Activities of Hemicellulose Polysaccharide from Astragalus radix Herb Residue.Molecules. 2019 Oct 9;24(20):3644. doi: 10.3390/molecules24203644. Molecules. 2019. PMID: 31601012 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials